3 recruiting, 2 completed, 1 active not recruiting, 1 enrolling by invitation. 2 Phase 4, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Completed 1, Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Biologics: new trials by email Literature Review of Biologics trials Research Report on Biologics
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Continuous HRV Monitoring for Predicting Response to Biologic Therapy in IBD Inflammatory Bowel Disease, Heart Rate Variability | Enrolling by invitation | Xijing Hospital | 100 | 2025-12-25 | 2026-03-16 | |
| Real-world Immunogenicity of Anti-IL5/5a Antibody Asthma, Immunogenicity | Active not recruiting | Samsung Medical Center | 100 | 2025-08-19 | 2026-05-05 | |
| A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular Biomarkers Prescreen platform, biologics treatment - Psoriasis, Psoriasis Arthritis | Phase 4 | Recruiting | Taichung Veterans General Hospital | 50 | 2025-07-29 | 2025-09-02 |
| A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP) Budoprutug - Immune Thrombocytopenia (ITP), ITP | Phase 1 / Phase 2 | Recruiting | Climb Bio, Inc. | 24 | 2025-06-30 | 2026-03-27 |
| A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA Biologic Agent - ABPA, Biologics | Recruiting | Qianfoshan Hospital | 50 | 2025-01-31 | 2026-04-17 | |
| Quantify the Value of Transmural Inflammation in the Treatment of Crohn's Disease With Ustekinumab:an Analysis Based on Imaging Science Inflammatory Bowel Diseases, Crohn Disease | Completed | Sixth Affiliated Hospital, Sun Yat-sen University | 150 | 2022-07-01 | 2026-04-29 | |
| Efficacy of Mesalazine Combined With Biologics in the Treatment of Moderate to Severe Ulcerative Colitis Infliximab, Vedolizumab, Mesalazine - Ulcerative Colitis, Efficacy, Self | Phase 4 | Completed | Sixth Affiliated Hospital, Sun Yat-sen University | 438 | 2022-01-15 | 2026-04-29 |
| Tofacitinib Registry of Patients With Ulcerative Colitis in Germany Colitis, Ulcerative, Biologics | Terminated | Ced Service GmbH | 50 | 2019-08-01 | 2021-10-08 |
Inflammatory Bowel Diseases (3) · Colitis, Ulcerative (2) · Arthritis, Psoriatic (1) · Aspergillosis, Allergic Bronchopulmonary (1) · Asthma (1) · Crohn Disease (1) · Intestinal Diseases (1) · Invasive Pulmonary Aspergillosis (1) · Psoriasis (1) · Purpura, Thrombocytopenic, Idiopathic (1) · Sleep Initiation and Maintenance Disorders (1)
Digestive System Diseases (4) · Gastroenteritis (4) · Gastrointestinal Diseases (4) · Immune System Diseases (3) · Intestinal Diseases (3) · Colitis (2) · Colonic Diseases (2) · Hypersensitivity (2) · Hypersensitivity, Immediate (2) · Lung Diseases (2) · Respiratory Hypersensitivity (2) · Respiratory Tract Diseases (2) · Arthritis (1) · Aspergillosis (1) · Autoimmune Diseases (1)
Biological Factors (1) · Infliximab (1) · Mesalamine (1) · vedolizumab (1)
Sixth Affiliated Hospital, Sun Yat-sen University (2) · Ced Service GmbH (1) · Climb Bio, Inc. (1) · Qianfoshan Hospital (1) · Samsung Medical Center (1) · Taichung Veterans General Hospital (1) · Xijing Hospital (1)
China (4) · Bulgaria (1) · Germany (1) · Greece (1) · Serbia (1) · South Korea (1) · Spain (1) · Taiwan (1) · Ukraine (1)